SGLT2抑制剂作为1型糖尿病辅助治疗:获益与风险的平衡
本文汇总了卡格列净、达格列净、恩格列净和索格列净在1型糖尿病患者中的八项临床试验数据。SGLT2抑制剂在8-12周时降HbA1c效果最明显,但随治疗时间延长(至52周)效果减弱;同时糖尿病酮症酸中毒风险约增加六倍,FDA估计索格列净每26患者年暴露新增一例酮症酸中毒。
要点
- SGLT2抑制剂辅助胰岛素治疗1型糖尿病可降HbA1c,但疗效随疗程延长而减弱。
- 治疗显著增加糖尿病酮症酸中毒风险,约六倍。
- 长期血糖疗效维持时间数据尚缺乏。
核心结论
- SGLT2抑制剂作为1型糖尿病辅助治疗虽有降糖获益,但酮症酸中毒风险显著增加,需权衡风险获益。
研究设计与样本
- 本文为Personal View,汇总了卡格列净、达格列净、恩格列净和索格列净在1型糖尿病患者中的八项临床试验数据。
主要发现
- HbA1c降低疗效在治疗8-12周时最大,但随治疗时间延长(至52周)降幅减弱。
- SGLT2抑制剂治疗导致严重不良事件,包括糖尿病酮症酸中毒风险约增加六倍。
- 美国食品药品监督管理局估计,索格列净治疗每26患者年暴露新增一例酮症酸中毒。
关键数值与推荐
- HbA1c降低疗效在8-12周时最大,至52周时减弱。
- 糖尿病酮症酸中毒风险约增加六倍。
- 索格列净每26患者年暴露新增一例酮症酸中毒。
临床怎么用
- 临床使用SGLT2抑制剂辅助治疗1型糖尿病时,应密切监测酮症酸中毒风险,并评估患者获益与风险的平衡。
局限性
- 尚缺乏数据确定1型糖尿病患者长期治疗中血糖疗效能维持多久。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several beneficial effects in patients with type 2 diabetes, including glucose lowering, weight loss, blood pressure lowering, and a reduced risk of major adverse cardiovascular events. To address high unmet medical need via improved glycaemic control, several clinical trials have been done to assess the efficacy and safety of SGLT2 inhibitors in combination with insulin therapy in patients with type 1 diabetes. In this Personal View, we summarise data from eight clinical trials of canagliflozin, dapagliflozin, empagliflozin, and sotagliflozin in patients with type 1 diabetes. HbA1c-lowering efficacy was greatest at 8-12 weeks of therapy, but the magnitude of HbA1c lowering waned with longer duration of treatment (up to 52 weeks). Data are not yet available to establish for how long glycaemic efficacy could be sustained during long-term therapy in patients with type 1 diabetes. Moreover, SGLT2 inhibitor therapy induces serious adverse events, including a roughly six-times increased risk of diabetic ketoacidosis. The US Food and Drug Administration estimated that one additional case of ketoacidosis will occur for every 26 patient-years of exposure of patients with type 1 diabetes to sotagliflozin therapy. Assuming a case mortality of 0·4%, this estimate translates into 16 additional deaths per year per 100 000 patients with type 1 diabetes undergoing treatment. These considerations raise important questions about the risk-to-benefit profile of SGLT2 inhibitors when used as adjunctive therapy in patients with type 1 diabetes.
引用
- Taylor SI, Blau JE, Rother KI, et al. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019. PMID: 31585721. doi:10.1016/S2213-8587(19)30154-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。